These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 2928348)

  • 1. The envelope proteins from purified respiratory syncytial virus protect mice from intranasal virus challenge.
    Levine S; Dillman TR; Montgomery PC
    Proc Soc Exp Biol Med; 1989 Apr; 190(4):349-56. PubMed ID: 2928348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.
    Stott EJ; Taylor G; Ball LA; Anderson K; Young KK; King AM; Wertz GW
    J Virol; 1987 Dec; 61(12):3855-61. PubMed ID: 3316707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cotton rats previously immunized with a chimeric RSV FG glycoprotein develop enhanced pulmonary pathology when infected with RSV, a phenomenon not encountered following immunization with vaccinia--RSV recombinants or RSV.
    Connors M; Collins PL; Firestone CY; Sotnikov AV; Waitze A; Davis AR; Hung PP; Chanock RM; Murphy BR
    Vaccine; 1992; 10(7):475-84. PubMed ID: 1609551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The purification of four respiratory syncytial virus proteins and their evaluation as protective agents against experimental infection in BALB/c mice.
    Routledge EG; Willcocks MM; Samson AC; Morgan L; Scott R; Anderson JJ; Toms GL
    J Gen Virol; 1988 Feb; 69 ( Pt 2)():293-303. PubMed ID: 3339327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
    Murphy BR; Sotnikov A; Paradiso PR; Hildreth SW; Jenson AB; Baggs RB; Lawrence L; Zubak JJ; Chanock RM; Beeler JA
    Vaccine; 1989 Dec; 7(6):533-40. PubMed ID: 2692334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pulmonary immune response of Balb/c mice vaccinated with the fusion protein of respiratory syncytial virus.
    Hancock GE; Hahn DJ; Speelman DJ; Hildreth SW; Pillai S; McQueen K
    Vaccine; 1994; 12(3):267-74. PubMed ID: 8165859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The response of infants with bronchiolitis to the proteins of respiratory syncytial virus.
    Levine S; Dajani A; Klaiber-Franco R
    J Gen Virol; 1988 Jun; 69 ( Pt 6)():1229-39. PubMed ID: 3385405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of BALB/c mice from respiratory syncytial virus infection by immunization with a synthetic peptide derived from the G glycoprotein.
    Trudel M; Nadon F; Séguin C; Binz H
    Virology; 1991 Dec; 185(2):749-57. PubMed ID: 1720589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection.
    Hancock GE; Speelman DJ; Frenchick PJ; Mineo-Kuhn MM; Baggs RB; Hahn DJ
    Vaccine; 1995 Mar; 13(4):391-400. PubMed ID: 7793137
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization.
    Murphy BR; Sotnikov AV; Lawrence LA; Banks SM; Prince GA
    Vaccine; 1990 Oct; 8(5):497-502. PubMed ID: 2251875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.
    Connors M; Kulkarni AB; Collins PL; Firestone CY; Holmes KL; Morse HC; Murphy BR
    J Virol; 1992 Feb; 66(2):1277-81. PubMed ID: 1731105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chimeric glycoprotein formulated with a combination adjuvant induces protective immunity against both human respiratory syncytial virus and parainfluenza virus type 3.
    Garg R; Brownlie R; Latimer L; Gerdts V; Potter A; van Drunen Littel-van den Hurk S
    Antiviral Res; 2018 Oct; 158():78-87. PubMed ID: 30071204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of administration dose and route on the immunogenicity and protective efficacy of BBG2Na, a recombinant respiratory syncytial virus subunit vaccine candidate.
    Goetsch L; Plotnicky-Gilquin H; Champion T; Beck A; Corvaïa N; Stâhl S; Bonnefoy JY; Nguyen TN; Power UF
    Vaccine; 2000 Jun; 18(24):2735-42. PubMed ID: 10781861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partial protection to respiratory syncytial virus (RSV) elicited in mice by intranasal immunization using live staphylococci with surface-displayed RSV-peptides.
    Cano F; Plotnicky-Gilquin H; Nguyen TN; Liljeqvist S; Samuelson P; Bonnefoy J; Stâhl S; Robert A
    Vaccine; 2000 Jun; 18(24):2743-52. PubMed ID: 10781862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children.
    Belshe RB; Anderson EL; Walsh EE
    J Infect Dis; 1993 Oct; 168(4):1024-9. PubMed ID: 8376814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bovine respiratory syncytial virus protects cotton rats against human respiratory syncytial virus infection.
    Piazza FM; Johnson SA; Darnell ME; Porter DD; Hemming VG; Prince GA
    J Virol; 1993 Mar; 67(3):1503-10. PubMed ID: 8437227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The immunogenicity of subunit vaccines for respiratory syncytial virus after co-formulation with aluminum hydroxide adjuvant and recombinant interleukin-12.
    Hancock GE; Smith JD; Heers KM
    Viral Immunol; 2000; 13(1):57-72. PubMed ID: 10733169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.
    Hancock GE; Speelman DJ; Heers K; Bortell E; Smith J; Cosco C
    J Virol; 1996 Nov; 70(11):7783-91. PubMed ID: 8892899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic peptides corresponding to the F protein of RSV stimulate murine B and T cells but fail to confer protection.
    Trudel M; Stott EJ; Taylor G; Oth D; Mercier G; Nadon F; Séguin C; Simard C; Lacroix M
    Arch Virol; 1991; 117(1-2):59-71. PubMed ID: 1706591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses.
    Hu KF; Elvander M; Merza M; Akerblom L; Brandenburg A; Morein B
    Clin Exp Immunol; 1998 Aug; 113(2):235-43. PubMed ID: 9717973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.